Transarterialchemoembolization(TACE)combinedwithcamrelizumabandapatinibversusTACEaloneinthetreatmentofunresectablehepatocellularcarcinomaeligibleforembolization:Amulticenter,open-label,randomized,phase2study(CAP-ACE).
经动脉化疗栓塞（TACE）联合卡瑞利珠单抗和阿帕替尼对比单纯TACE治疗符合栓塞条件的不可切除肝细胞癌：一项多中心、开放标签、随机、II期研究（CAP-ACE）
讲者：滕皋军东南大学附属中大医院
Postersession
摘要号：531
MRIimagingandmachinelearningbasedradiomicsfordetectionofmixedHCCandCCAtumors:Stillaneedforliverbiopsy
讲者：YuquanQian中国医学科学院肿瘤医院
02
摘要号：533
DevelopmentandvalidationoftheSPEARscoringmodelandpredictingoverallsurvivalinunresectablehepatocellularcarcinomapatientstreatedwithTACE,moleculartargetedtherapies,andimmunecheckpointinhibitors.
讲者：WenliLi南方医科大学南方医院
03
摘要号：541
Regorafenibcombinedwithimmunotherapyandprognosisofunresectablehepatocellularcarcinoma.
讲者：TianxiangLi青岛大学附属医院
04
摘要号：542
Concurrenttransarterialchemoembolizationplusatezolizumabandbevacizumabinunresectablehepatocellularcarcinoma:Interimanalysisfromamulticenterreal-worldstudy(CHANCE023).
讲者：RongYan东南大学附属中大医院
05
摘要号：553
ComparisonofefficacyandsafetyofPD-1andPD-L1antibodiesincombinationwithhepaticarterialinfusionchemotherapyandtargettherapyforunresectableintrahepaticcholangiocarcinoma:Amulticenterretrospectivestudy.
讲者：XinhaoXiong中山大学肿瘤防治中心
06
摘要号：562
AglobalcomparativestudyonMDTpracticesinthemanagementofhepatocellularcarcinomainhigh-incomecountries(HICs)andlow-andmiddle-incomecountries(LMICs).
讲者：HuangZhiyong华中科技大学同济医学院附属同济医院
07
摘要号：563
Leadingtheway:HowleadingChineseinstitutionsdriveMDTexcellenceinhepatocellularcarcinoma.
讲者：JiapingLi中山大学附属第一医院
08
摘要号：568
PromptinitiationofdurvalumabandtremelimumabtreatmentforunresectablehepatocellularcarcinomainpatientswithchronicactivehepatitisB.
讲者：Yu-YunShao台湾大学医学院附设医院
09
摘要号：570
Adjuvantchemoradiationcombinedwithimmunotherapyforpatientswithhigh-riskresectableextrahepaticcholangiocarcinomaandgallbladdercancer:AphaseII,multicenter,randomizedcontrolledtrial(ACCORDtrial).
讲者：匡铭中山大学附属第一医院
10
摘要号：571
UpdatedresultsofthePATHstudy:AdjuvanttherapywithdonafenibplusaPD-1inhibitorforpatientswithhepatocellularcarcinomaathighriskofrecurrenceafterresection.
讲者：YiwenChen浙江大学医学院附属第一医院
11
摘要号：576
First-linedurvalumabwitharterialchemotherapyinmajorportalinvadedhepatocellularcarcinoma:Thephase2DurHopestudywithbiomolecularanalyses.
讲者：赵明中山大学肿瘤防治中心
12
摘要号：579
First-lineiparomlimabandtuvonralimab(QL1706)oriparomlimab(QL1604)+bevacizumab(BEV)forunresectablehepatocellularcarcinoma(HCC):UpdatedresultsfromthephaseIb/IIDUBHE-H-106study.
讲者：毕锋四川大学华西医院
13
摘要号：580
Lenvatinibplushepaticarterialinfusionchemotherapyofoxaliplatin,fluorouracil,andleucovorinversuslenvatinibaloneforadvancedhepatocellularcarcinoma.
讲者：FengShi广东省人民医院
14
摘要号：581
Selectiveinternalradiationtherapywithyttrium-90resinmicrospheresfollowedbylenvatinibplusPD-1inhibitorforlargeorhugeadvanced-stagehepatocellularcarcinoma:AretrospectivecohortstudyfromChina.
讲者：JingjunHuang广州医科大学附属第二医院
15
摘要号：585
Currentstatusofphysicians’perceptionofHCCconversion/downstagingtherapy:AnationwidesurveyinChina.
讲者：XinyuBi中国医学科学院肿瘤医院
16
摘要号：588
UpdatedresultsfromALTER-H004study:AnlotinibcombinedwithTACEasadjuvanttherapyinpatientswithhepatocellularcarcinoma(HCC)athighriskofrecurrenceaftersurgery—Asinglearm,multi-center,phaseIIclinicaltrial.
讲者：ZhengWu西安交通大学第一附属医院
17
摘要号：593
Surufatinibcombinedwithlocoregionaltherapiesandimmunecheckpointinhibitor(ICI)fortreatingunresectableormetastaticintrahepaticcholangiocarcinoma.
讲者：WanGuangZhang华中科技大学同济医学院附属同济医院
18
摘要号：595
Efficacyandsafetyofdurvalumabandgemcitabine-basedchemotherapycombinedwithorwithoutlenvatinibinadvancedbiliarytractcancer.
讲者：HaobinYu中国科学技术大学附属第一医院
19
摘要号：600
Long-termsurvivaloutcomesofatezolizumabplusbevacizumabtreatmentinpatientswithadvancedhepatocellularcarcinoma.
讲者：Ching-TsoChen台湾大学医学院附设医院新竹台大分院
20
摘要号：601
UpdatedresultsofALTER-H006:AphaseIIstudyofbenmelstobart(PD-L1inhibitor)plusanlotinibasadjuvanttherapyinhepatocellularcarcinoma(HCC)withhighriskofrecurrenceafterradicalresection.
讲者：XianhaiMao中南大学湘雅医学院附属肿瘤医院
21
摘要号：622
AssociationofGPR120andNGFwithperineuralinvasionincholangiocarcinoma:Clinicalandexperimentalinsights.
讲者：JunHe苏州大学附属第一医院
22
摘要号：632
ExploringNectin-4expressioninhepatocellularcarcinoma.
讲者：ChienHuaiChuang台湾大学癌症中心
23
摘要号：657
Efficacyandsafetyofsurufatinibinunresectableormetastaticgrade3pancreaticneuroendocrinetumors(NETG3):Real-worldanalysis.
讲者：JianWang山东大学齐鲁医院
24
摘要号：714
Thevalueandindicationsforsurgeryinpancreaticcancerwithsynchronouslivermetastases.
讲者：RuiliWei中日友好医院
25
摘要号：729
PreliminaryresultofaphaseIbstudy:EfficacyandsafetyofFG-M108plusgemcitabine/nab-paclitaxelasfirst-line(1L)treatmentinpatientswithClaudin18.2-positivelocallyadvancedunresectableormetastatic(LA/m)pancreaticcancer.
讲者：刘福囝中国医科大学附属第一医院
26
摘要号：734
Theeffectofrenin-angiotensinsysteminhibitorsonpatientswithpancreaticcancerreceivingsystemictreatment:AretrospectivecohortstudyfromTriNetXUScollaborativenetworks.
讲者：Cheng-WeiChou台中荣民总医院
27
摘要号：739
SurufatinibcombinedwithTAS-102asalate-linetherapyinpatientswithmetastaticpancreaticcancer(mPDAC):Updatedresultsofasingle-arm,phaseIItrial.
讲者：张东生中山大学肿瘤防治中心
28
摘要号：740
ChidamideplusenvafolimabcombinedwithS-1assecond-linetreatmentinadvancedandmetastaticpancreaticcancer(P-henomS/SCOG-P002):Asingle-arm,exploratory,multicenter,phase2trial—Interimreport.
讲者：WeiLi苏州大学附属第一医院
29
摘要号：774
PersonalizedctDNAmonitoringtoassesstherecurrenceofearlystagepancreaticcanceraftersurgery.
讲者：杜娟南京鼓楼医院
TrialsinProgressPosterSession
摘要号：TPS650
AMBERpart2F:Cobolimabincombinationwithdostarlimabintreatment-navepatientswithlocallyadvanced/metastaticand/orunresectablehepatocellularcarcinoma(HCC).
讲者：StephenLamChan香港中文大学
备注：排名不分先后，按照摘要号进行排序
如有遗漏或任何问题，请给我们留言~
撰写：Babel
排版：Aurora
执行：Babel
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。